Communicable Diseases

 

Avian Influenza

 

Updates

 

FAQ

 

Guidelines

 

Meetings

 

Links

 

Contact Details

Avian Influenza

Prevention and Control of Influenza due to Avian Influenza Virus A (H5N1)

*      Annex 3 :  WHO guidelines for the storage and transport of human and animal specimens for laboratory diagnosis of influenza A/H5 infection

 

Specimen storage

Specimens in viral transport medium for viral isolation should be kept at 4 °C and transported to the laboratory promptly. If specimens are transported to the laboratory within 2 days, they may be kept at 4 °C; otherwise they should be frozen at or below –70 °C until they can be transported to the laboratory.  Repeated freezing and thawing must be avoided to prevent loss of infectivity. Sera may be stored at 4 °C for approximately one week, but thereafter should be frozen at –20 °C.

Specimens should be collected and transported in a suitable transport medium on ice or in liquid nitrogen. Specimens for influenza should not be stored or shipped in dry ice (solid carbon dioxide) unless they are sealed in glass or sealed, taped and double plastic-bagged. Carbon dioxide can rapidly inactivate influenza viruses if it gains access to the specimens through shrinkage of tubes during freezing.

Specimen transport

Transport of specimens should comply with WHO guidelines for the safe transport of infectious substances and diagnostic specimens (WHO, 1997), available at  http://www.who.int/emc/pdfs/emc97_3.pdf

The receiving laboratory should be notified before shipment of specimens.

Transport of specimens within national borders should comply with the procedures detailed within each country’s regulations.

International air transport of human specimens from suspect or probable highly pathogenic avian influenza (HPAI) H5 cases, or of specimens from HPAI H5 infected animals must follow the current edition of the International Air Transport Association (IATA) Dangerous Goods Regulations.

*    Dangerous goods index

*    Consignment of diagnostic specimens 2003

 

The IATA Regulations of 2003 (available at  http://www.iata.org/NR/ContentConnector/CS2000/SiteInterface/pdf/cargo/dg/
Consignment_diagnostic_specimens_2003.pdf
) allow specimens known or suspected to contain the HPAI H5 agent to be transported as UN 3373 “diagnostic specimens” when they are transported for diagnostic or investigational purposes.

Specimens transported for any other purposes, and cultures (as defined in the IATA Regulations) prepared for the deliberate generation of pathogens, must be transported as UN 2814 or UN 2900, as appropriate.

All specimens to be transported (UN 3373, UN 2900, or UN 2814) must be packaged in triple packaging consisting of three packaging layers (see  http://www.iata.org/dangerousgoods/index ).

 

UN 3373, Diagnostic Specimens, shall be packed in good quality packaging, which shall be strong enough to withstand the shocks and loads normally encountered during transport. Packaging shall be constructed and closed so as to prevent any loss of contents that might be caused under normal conditions of transport, by vibration or by changes in temperature, humidity or pressure.

*     Primary receptacle(s) must be water tight, e.g., if screw cap seal with parafilm or similar.

*     Multiple primary receptacles must be wrapped individually to prevent breakage.

*     Use enough absorbent material to absorb the entire contents of all primary receptacles in case of leakage or damage

 

Proper packing and labeling of the secondary container for shipping of diagnostic

The labeling for contents should include the words:

“UN 3373 Diagnostic Specimens”

In order to minimise possible loss of usefulness in specimens for further assays during the transportation period, it is advised to ship samples packed preferably with dry ice, or alternatively with enough amount of frozen ice packs/refrigerant. Detail packing, documentation, and handling requirements for the international transport of infectious materials as contained in the regulations of the International Air Transport Association (IATA) and in documentation of the International Health Regulations (IHR).

For liquids

The primary receptacle(s) shall be leakproof and shall not contain more than 500 ml. There shall be absorbent material placed between the primary receptacle and the secondary packaging; if several fragile primary receptacles are placed in a single secondary packaging, they shall be either individually wrapped or separated so as to prevent contact between them. The absorbent material shall be in sufficient quantity to absorb the entire contents of the primary receptacles and there shall be a secondary packaging that shall be leakproof. The primary receptacle or the secondary packaging shall be capable of withstanding without leakage an internal pressure producing a pressure differential of not less than 95 kPa (0.95 bar). The outer packaging shall not contain more than 4 litres.

 

For solids

The primary receptacle(s) shall be sift-proof and shall not contain more than 500 g. If several fragile primary receptacles are placed in a single secondary packaging, they shall be either individually wrapped or separated so as to prevent contact between them and there shall be a secondary packaging which shall be leakproof. The outer packaging shall not contain more than 4 kg.

For air transport, the smallest overall external dimension of a completed package must be at least 10 cm.

Packaging must conform to certain performance standards.

For further information about definitions, packaging requirements, markings and labels, accompanying documentation, and refrigerants, please refer to the competent authority, current IATA shipping guidelines, commercial packaging suppliers, or available courier companies.

*      Annex 4 : Contact details for reporting to WHO

 

WHO Headquarters, Geneva

 

Global Alert and Response Team

Mobile: +41 79 500 6540

Fax: +41 22 791 1397

E-mail: outbreak@who.int

 

Global Influenza Programme

Tel: +41 22 791 3004

Fax: + 41 22 791 4878

E-mail: influenza@who.int

 

Regional Offices

 

WHO Regional Office for Africa-AFRO

Dr Paul Lusamba-Dikassa

Regional Adviser, Communicable Disease Surveillance and Response

Tel: +263 4 746 000/011/070

Fax +263 4 746 867/127

E-mail: lusambap@whoafr.org

 

Regional Office for the Americas/Pan American Health Organization-AMRO/PAHO

Dr Marlo Libel

Regional Adviser in Communicable Diseases, Disease Prevention and Control

Tel: +1 202 974 3129

Fax: +1 202 974 3259

E-mail: libelmar@paho.org

 

Regional Office for the Eastern Mediterranean-EMRO

Dr H. El Mahdi El Bushra

Regional Adviser, Communicable Disease Surveillance and Response

Tel: +20 2 276 52 91

Fax: +20 2 276 54 14

E-mail: elbushrah@emro.who.int

 

Regional Office for Europe-EURO

Dr Bernardus Ganter

Regional Adviser, Communicable Diseases

Tel: +45 39 17 13 98

Fax: +45 3917 18 51

E-mail: bga@who.dk

 

Regional Office for South-East Asia-SEARO

Dr M.V.H. Gunaratne

Regional Adviser on Communicable Disease Surveillance and Response

Tel: +91 11 337 0804

Fax: +91 11 337 8438

E-mail: gunaratnem@whosea.org

 

Regional Office for the Western Pacific-WPRO

Dr Hitoshi Oshitani

Regional Adviser in Communicable Disease Surveillance and Response

Tel: +632 528 9730/9964

Fax: +632 521 1036

E-mail: oshitanih@wpro.who.int  and outbreak@wpro.who.int

 

||| | ||